MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
OCX - OncoCyte Corp
$5.10
-0.75(-12.82%)9:00:00 PM 1/26/2021
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • RSI is at a high level of 74. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    01/20/2021OCX
    Oncocyte Announces $25 Million Registered Offering

    Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum IRVINE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it ha...

    01/12/2021OCX
    Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference

    IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 23rd Annual Needham Virtual Growth Conference. Presentation details: Date: January 15, 2021 Time: 10:45am ESTInvestors can register for the conference here: https://wsw.com/webcast/needham103/ocx/Follow...

    12/17/2020OCX
    Do Options Traders Know Something About OncoCyte (OCX) Stock We Don't?

    Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

    12/15/2020OCX
    Oncocyte Soars on Licensing Deal With Chinese Firm

    The cancer detection company said it has licensed a lung cancer test to China's Burning Rock Biotech.

    12/15/2020OCX
    ROCE Insights For OncoCyte Corporation Common Stock

    In Q3, OncoCyte Corporation Common Stock (AMEX: OCX) posted sales of $555.00 thousand. Earnings were up 5.2%, but OncoCyte Corporation Common Stock still reported an overall loss of $9.22 million. OncoCyte Corporation Common Stock collected $143.00 thousand in revenue during Q2, but reported earnings showed a $8.77 million loss.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts i...

    12/15/2020OCX
    OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares

    Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement with China-based Burning Rock Biotech Ltd. to bring OncoCyte's DetermaRX test for early-stage lung cancer patients to China. Trading volume spiked to 8.3 million shares, compared with the full-day average of about 419,500 shares. "This agreement with Burning Rock accelerates the ongoing expansi...

    12/15/2020OCX
    Oncocyte to Present at the 15th Annual LD Micro Main Event

    IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference. Presentation details: Date: Tuesday, December 15, 2020 Time: 12:40 – 1:00PM ESTInvestors can register for the conference HERE.     Following the conference...

    12/15/2020OCX
    Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China

    Aligns Oncocyte with one of China’s fastest growing NGS-based cancer therapy selection companies; China is considered to be the world’s largest early-stage lung cancer market Exclusive agreement includes payments of up to $6M in the first year and ongoing per test feesIRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum...

    12/15/2020OCX
    Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China

    GUANGZHOU, China, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx™, a risk stratification test for early stage lung cancer patients, to China. Even though early-stage non-small-cell lung cancer (NSCLC) generally demonstrates a good prognosis after surgery, a significant proportion of early-stage NSCL...